
Mark Gabriel Lebwohl MD
Dean for Clinical Therapeutics, Professor and Chairman Emeritus of Dermatology, Icahn School of Medicine at Mount Sinai
5 e 98 stNew York, NY 10029
Overview of Dr. Lebwohl
Dr. Mark Lebwohl is a dermatologist in New York, NY and is affiliated with multiple hospitals in the area, including The Mount Sinai Hospital, Mount Sinai West, Mount Sinai Morningside, Mount Sinai Beth Israel, Mount Sinai Hospital of Queens, New York Eye and Ear Infirmary of Mount Sinai, and Mount Sinai Brooklyn. He received his medical degree from Harvard Medical School and has been in practice 45 years. He is one of 53 doctors at Mount Sinai Brooklyn and one of 23 doctors at New York Eye and Ear Infirmary of Mount Sinai who specialize in Dermatology. He has more than 100 publications and over 500 citings.
Education & Training
- Icahn School of Medicine at Mount SinaiResidency, Dermatology, 1981 - 1983
- Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Internal Medicine, 1978 - 1981
- Harvard Medical SchoolClass of 1978
Certifications & Licensure
- NY State Medical License 1980 - 2027
- American Board of Dermatology Dermatology
- American Board of Internal Medicine Internal Medicine
Awards, Honors, & Recognition
- Gold Medal American Academy of Dermatology, 2022
- Top MD Consumers Checkbook
- Whos Who in Medicine and Healthcare Marquis Whos Who
- Join now to see all
Clinical Trials
Publications & Presentations
PubMed
- Correction to: Repeated Switching Between CT-P17 and EU Reference Adalimumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, ...Mark G Lebwohl, John Y Koo, Janusz Jaworski, Jakub Trefler, Stefan Daniluk
Advances in Therapy. 2025-07-12 - Ixekizumab and Malignant Neoplasms: A Pooled Analysis of Data From 25 Randomized Clinical Trials.Joseph F Merola, Kim A Papp, Atul Deodhar, Andrew Blauvelt, Andris Kronbergs
JAMA Dermatology. 2025-07-09 - 6 citationsDeucravacitinib in plaque psoriasis: Four-year safety and efficacy results from the Phase 3 POETYK PSO-1, PSO-2 and long-term extension trials.April W Armstrong, Mark Lebwohl, Richard B Warren, Howard Sofen, Akimichi Morita
Journal of the European Academy of Dermatology and Venereology. 2025-07-01
Authored Content
- How Dermatologists Can Address Obesity to Improve Psoriasis OutcomesMarch 2025
Press Mentions
- Decision Trees for Psoriasis: Is There One Best Drug?April 25th, 2025
- Risankizumab Makes a Difference in Hard-to-Treat PsoriasisMarch 21st, 2025
- Anti–IL-23 Therapy Might Emerge as Best Biologic in Psoriasis if Used Early and at High DosesMarch 20th, 2025
- Join now to see all
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: